<DOC>
	<DOCNO>NCT02914262</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled , single ascend dose , Phase I study healthy male subject .</brief_summary>
	<brief_title>Single Ascending Dose Study Assess Safety , Tolerability , PK PD Effects Male Volunteers</brief_title>
	<detailed_description>Single oral dos AKB-4924 investigate 6 sequential cohort 8 healthy male subject . Primarily 6 dose level plan ; propose dose 20 mg , 60 mg , 120 mg , 240 mg , 360 mg , 480 mg. Actual dose may decrease increase base safety tolerability drug , determine Investigator Sponsor . Additional cohort may add needed test lower , high , repeat dos .</detailed_description>
	<criteria>1 . Healthy male subject 18 49 year age , inclusive . 2 . Body mass index ( BMI ) 18 30 kg/m2 , inclusive . 3 . Understands procedures requirement study provide write informed consent authorization protect health information disclosure . 1 . Nonvasectomized male subject female partner unable unwilling use acceptable method contraception ( described Section 8.1.3 , Contraception Pregnancy Avoidance Measures ) study 30 day follow last dose study medication . 2 . Evidence active infection , unless medical monitor Investigator agree subject appropriate study . 3 . Current past history chronic disease include , limited , gastrointestinal , cardiovascular , cerebrovascular , pulmonary , neurologic , renal , liver disease . 4 . Diastolic blood pressure ≤55 mmHg systolic blood pressure ≤100 mmHg Screening . 5 . Clinically important significant conduction abnormality ECG Screening ( include QTcF interval &gt; 450 msec ) and/or history long QT syndrome . It acceptable repeat ECG confirm finding . 6 . Any history malignancy previous 5 year except curatively resect basal cell carcinoma skin squamous cell carcinoma skin , resect benign colonic polyp . 7 . Seropositive human immunodeficiency virus ( HIV ) , Hepatitis B surface antigen ( HBsAg ) , Hepatitis C virus ( HCV ) antibody . 8 . Serum transaminase ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] ) level &gt; 1.5X upper limit normal ( ULN ) . If subject present abnormal AST and/or ALT result , subject may reschedule test may repeat discretion Investigator . 9 . Serum creatinine level ≥1.50 mg/dL . It acceptable repeat test confirm finding . 10 . Chronic daily medication use , except daily counter multivitamin supplement . 11 . Subject take prescription medication within 7 day ( 5 halflives , whichever long ) prior admission CRU . 12 . Herbal supplement within 48 hour prior dose study drug . 13 . History regular alcohol consumption exceed 14 drinks/week ( 1 drink = 5 ounce wine 12 ounce [ 360 mL ] beer 1.5 ounce [ 45 mL ] hard liquor ) within 6 month Screening . 14 . Any history alcohol drug dependence within previous year prior Screening . Selfreported substance alcohol dependence ( exclude nicotine caffeine ) within past 2 year , and/or ever substance alcohol rehabilitation program treat substance alcohol dependence 15 . Any use alcohol within 48 hour admission CRU . 16 . Consumption food beverage contain caffeine 24 hour prior dose last sample collect Treatment period . 17 . Subjects know history smoking and/or use nicotine nicotinecontaining product within past 6 month . 18 . Positive screen drug abuse positive alcohol cotinine result screen Day 1 . 19 . Donation blood blood product 4 week prior dose study drug . 20 . Physical activity great normal level activity 48 hour prior admission CRU . 21 . Use investigational medication device participation investigational study within 30 day 5 halflives investigational medication , whichever longer , precede Day 1 , ongoing schedule participation another investigational study present study Day 8 FollowUp . 22 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration may interfere interpretation study result , Investigator 's judgment , would make subject inappropriate study entry . 23 . Known allergy HPβCD .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>